This is Tumour223's Typepad Profile.
Join Typepad and start following Tumour223's activity
Join Now!
Already a member? Sign In
Recent Activity
BioMarin perfects the popular rare disease drug model BioMarin snares orphan drug upstart in $115M buyout Biotech companies are aiming to capitalize on the drugmakers big appetites for rare disease drugs. For example, Alnylam ($ALNY) last weekrevealedthat its RNA-interference drug for the rare disorder transthyretin-mediated amyloidosis is now one of... Continue reading
Tumour223 is now following Estoy Loco N
Jan 30, 2012
Tumour223 is now following Alan Wahri
Jan 30, 2012